Public listing of Nordic Nanovector ASA at Oslo Børs

Nordic Nanovector’s mission is to develop and commercialize innovative radioimmunotherapeutics that target difficult to treat cancers using the Company’s proprietary nanovector targeting technology. The Company’s lead product candidate, Betalutin (TM) aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin Lymphoma (NHL).

Quotes, details on the share and the company, notifications and historical prices